Cowen & Co. Maintains Outperform on Thermo Fisher Scientific, Raises Price Target to $655
Cowen & Co. analyst Doug Schenkel maintains Thermo Fisher Scientific (NYSE:TMO) with a Outperform and raises the price target from $560 to $655.
BTIG Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $700
BTIG analyst Sung Ji Nam maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $610 to $700.
Analyst Ratings For Thermo Fisher Scientific
Within the last quarter, Thermo Fisher Scientific (NYSE:TMO) has observed the following analyst ratings:
10 Biggest Price Target Changes For Monday
Barclays boosted Upstart Holdings, Inc. (NASDAQ: UPST) price target from $230 to $345. Upstart shares fell 2.8% to $294.87 in pre-market trading.
48 Biggest Movers From Friday
Gainers
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Keybanc Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $710
Keybanc analyst Paul Knight maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and raises the price target from $555 to $710.
Why Thermo Fisher Shares Are Trading Higher Today
Thermo Fisher Scientific Inc (NYSE: TMO) is trading higher Friday after the company issued full-year 2022 financial guidance above analyst estimates.
25 Stocks Moving In Friday’s Mid-Day Session
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
Investor React Positively To Thermo Fisher’s Annual Guidance
Thermo Fisher Scientific Inc (NYSE:TMO) provided initial revenue and earnings guidance for 2022 while reiterating previously disclosed financial guidance for full-year…
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)